DARZALEX® IV (daratumumab) HCP

Pollux_Mobile_Trial_Page_Badge

DARZALEX^® + Revlimid^® (lenalidomide) + dexamethasone

Significant improvement in PFS using DARZALEX^®-based triplet therapy¹

PFS=progression-free survival; HR=hazard ratio.

Median PFS had not yet been reached with DARZALEX^® + Rd triplet therapy vs 18.4 months with Rd¹

Complete response rate more than doubled with DARZALEX^® + Rd

Almost all (91%) patients responded to DARZALEX^® + Rd¹

pollux_orr_chart2x_j3

pullox_chart_orr_mobile_j3

PR=partial response; VGPR=very good partial response; CR=complete response; sCR=stringent complete response.

Deeper and sustained responses were demonstrated with DARZALEX^® + Rd vs Rd¹

With DARZALEX^® + Rd, median time to first response was 1 month (range: 0.9 to 13 months), and median time to VGPR or better was 3.7 months (95% CI: 3.0, 3.8), and median time to CR or better was 13.2 months (95% CI: 10.6, not estimable [NE])^1-3

Median duration of response was not yet reached with DARZALEX^® + Rd (range: 1+ to 19.8+ months) vs 17.4 months with Rd (range: 1.4 to 18.5+ months), at a median follow-up of 13.5 months¹

Daratumumab (DARZALEX^®) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) as a preferred Category 1* therapeutic option for previously treated multiple myeloma^†

^*Category 1=based upon high-level evidence, there is uniform National Comprehensive Cancer Network^® (NCCN^®) consensus that the intervention is appropriate.

^†Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): Multiple Myeloma V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. To view the most recent and complete version of the guideline, go online to www.nccn.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

SAFETY PROFILE – POLLUX

CONTRAINDICATIONS

DARZALEX^® is contraindicated in patients with a history of severe hypersensitivity (eg, anaphylactic reactions) to daratumumab or any of the components of the formulation.

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions

DARZALEX^® can cause severe and/or serious infusion-related reactions including anaphylactic reactions. These reactions can be life-threatening, and fatal outcomes have been reported. In clinical trials (monotherapy and combination: N=2066), infusion-related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions. Less than 1% of patients had a Grade 3/4 infusion-related reaction at Week 2 or subsequent infusions. The median time to onset was 1.5 hours (range: 0 to 73 hours). Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX^®. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, tachycardia, headache, laryngeal edema, and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting, and nausea. Less common symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, and hypotension.

When DARZALEX^® dosing was interrupted in the setting of ASCT (CASSIOPEIA) for a median of 3.75 months (range: 2.4 to 6.9 months), upon re-initiation of DARZALEX^®, the incidence of infusion-related reactions was 11% for the first infusion following ASCT. Infusion-related reactions occurring at re-initiation of DARZALEX^® following ASCT were consistent in terms of symptoms and severity (Grade 3 or 4: <1%) with those reported in previous studies at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, ie, 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing infusion-related reactions on Day 1 of Week 1, 4% on Day 2 of Week 1, and 8% with subsequent infusions.

Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt DARZALEX^® infusion for reactions of any severity and institute medical management as needed. Permanently discontinue DARZALEX^® therapy if an anaphylactic reaction or life-threatening (Grade 4) reaction occurs and institute appropriate emergency care. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion.

To reduce the risk of delayed infusion-related reactions, administer oral corticosteroids to all patients following DARZALEX^® infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease.

Interference With Serological Testing

Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient’s serum. The determination of a patient’s ABO and Rh blood type is not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX^®. Type and screen patients prior to starting DARZALEX^®.

Neutropenia and Thrombocytopenia

DARZALEX^® may increase neutropenia and thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer’s prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX^® until recovery of neutrophils or for recovery of platelets.

Interference With Determination of Complete Response

Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein.

Embryo-Fetal Toxicity

Based on the mechanism of action, DARZALEX^® can cause fetal harm when administered to a pregnant woman. DARZALEX^® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX^® and for 3 months after the last dose.

The combination of DARZALEX^® with lenalidomide, pomalidomide, or thalidomide is contraindicated in pregnant women because lenalidomide, pomalidomide, and thalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, pomalidomide, or thalidomide prescribing information on use during pregnancy.

ADVERSE REACTIONS

The most frequently reported adverse reactions (incidence ≥20%) were: upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia. The most common hematologic laboratory abnormalities (≥40%) with DARZALEX^® are: neutropenia, lymphopenia, thrombocytopenia, leukopenia, and anemia.

Please click here to see the full Prescribing Information.

cp-60862v7

DARZALEX® + Rd Demonstrated Superior Efficacy vs Rd Alone

Significant improvement in PFS using DARZALEX®-based triplet therapy1

Complete response rate more than doubled with DARZALEX® + Rd

Almost all (91%) patients responded to DARZALEX® + Rd1

Deeper and sustained responses were demonstrated with DARZALEX® + Rd vs Rd1

DARZALEX^® + Rd Demonstrated Superior Efficacy vs Rd Alone

Significant improvement in PFS using DARZALEX^®-based triplet therapy¹

Complete response rate more than doubled with DARZALEX^® + Rd

Almost all (91%) patients responded to DARZALEX^® + Rd¹

Deeper and sustained responses were demonstrated with DARZALEX^® + Rd vs Rd¹